Table 1.
Baseline characteristics and outcomes of patients.
| Values | |
|---|---|
| Number of patients | 132 |
| Male | 77 (58.3) |
| Age (years) | 69.0 ± 12.2 |
| Risk factors | |
| Hypertension | 101 (76.5) |
| Atrial fibrillation/flutter | 35 (26.5) |
| Hyperlipidaemia | 82 (62.1) |
| Diabetes mellitus | 40 (30.3) |
| Previous stroke | 42 (31.8) |
| Active smoker | 32 (24.2) |
| Stroke severity | |
| NIHSS 0–5 | 37 (28.0) |
| NIHSS 6–10 | 48 (36.4) |
| NIHSS 11–15 | 21 (15.9) |
| NIHSS >15 | 23 (17.4) |
| Stroke etiology (TOAST) | |
| Small vessel occlusion | 14 (10.6) |
| Large vessel thrombosis | 49 (37.1) |
| Cardioembolic | 27 (20.5) |
| Undetermined | 42 (31.8) |
| Time from symptom onset to treatment with rtPA (min) | 160 ± 46 |
| Dose of rtPA (mg) | |
| Intravenous rtPA (n = 125) | 68.2 ± 14.9 |
| Intravenous and intraarterial rtPA (n = 7) | 61.6 ± 14.7 |
| Duration of thrombolysis (min) | 64 ± 10 |
| Imaging data (median; total range) | |
| ASPECT score on admission | 10 (7–10) |
| ASPECT score at 24 h | 9 (0–10) |
| Short-term functional outcome | |
| Favorable | 53 (40.2) |
| No change | 47 (36.6) |
| Unfavorable | 21 (15.9) |
| Death | 5 (3.8) |
| Undetermined | 6 (4.5) |
| Long-term functional outcome | |
| mRS 0–1 | 46 (34.8) |
| mRS 2–5 | 34 (25.8) |
| mRS 6 (death) | 29 (22.0) |
| Undetermined | 23 (17.4) |
| Mortality by day 14 | 18 (13.6) |
| Intracerebral hemorrhage (ECASS II) | |
| aSICH | 7 (5.3) |
| SICH | 6 (4.5) |
Data are expressed as mean ± standard deviation or number (percentage) unless otherwise stated. n, number; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; rtPA, recombinant tissue plasminogen activator; ASPECT, Alberta Stroke Program Early CT score; mRS, modified Rankin score; ECASS II, European Cooperative Acute Stroke Study II; aSICH, asymptomatic intracranial hemorrhage; SICH, symptomatic intracranial hemorrhage.